Risk of progression of early-stage mycosis fungoides, 10-year experience
Open Access
- 22 February 2024
- journal article
- research article
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (3) , 407-413
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysisJournal of Dermatological Treatment, 2018
- Mycosis fungoides—clinical and histopathologic features, differential diagnosis, and treatmentSeminars in Cutaneous Medicine and Surgery, 2018
- Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialThe Lancet, 2017
- Cuándo emplear PUVA o NB-UVB en micosis fungoideCES Medicina, 2016
- Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?British Journal of Dermatology, 2014
- Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)Journal of the American Academy of Dermatology, 2014
- Hypopigmented mycosis fungoides: a review of its clinical features and pathophysiologyAnais Brasileiros de Dermatologia, 2013
- Time course, clinical pathways, and long‐term hazards risk trends of disease progression in patients with classic mycosis fungoidesCancer, 2012
- Mycosis FungoidesArchives of Dermatology, 2000
- Prognostic factors and evaluation of mycosis fungoides and Sézary syndromeJournal of the American Academy of Dermatology, 1997